

IMPROVEMENT IN SELF-MANAGEMENT OF BIOLOGICAL DMARDs FOR PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS WHEN A PHARMACIST PARTICIPATES IN A MULTIDISCIPLINARY CONSULTATION



25th EAFP congress
23-28 March 2021

C. Bottois⁽¹⁾, J. Hubert⁽¹⁾, C. Lopez-Medina⁽²⁾, S. Dumas⁽¹⁾, S. Belo⁽¹⁾, C. Roux⁽²⁾,
M. Dougados⁽²⁾, O. Conort⁽¹⁾

(1) – Pharmacy, AP-HP.Centre – Université de Paris, Site COCHIN, 27 rue du faubourg Saint-Jacques – 75014 Paris
(2) – Rheumatology, AP-HP.Centre – Université de Paris, Site COCHIN, 27 rue du faubourg Saint-Jacques – 75014 Paris

Contact : cecile.bottois@aphp.fr

N° 6ER-027

ATC code: L03

BACKGROUND AND IMPORTANCE

Enhancement information for patients with chronic inflammatory arthritis (IA) on **the management of subcutaneous (SC) biological DMARDs (bDMARDs)** with the intervention of several successive health professionals should improve their necessary safety **knowledge and skills** for optimized self-management of their treatments.

AIM AND OBJECTIVES

- 1) To assess the pharmacist's contribution to improving **knowledge and skills** of patients with IA treated with SC bDMARDs during multidisciplinary consultation (MC).
- 2) To assess the impact on **therapeutic adherence** and **patient satisfaction**.

MATERIALS AND METHODS

Prospective, monocentric, 6 months-trial, approved by Ethical Committee, from October 2019 to July 2020

Inclusion criteria



Patient with IA
Under SC bDMARDs

Multidisciplinary consultation (M0)



Care
coordinator




Pharmacist



Rheumatologist

Aim = enhance patient's knowledge and adherence

Intervention



Self-administered questionnaires

- Biosecure (knowledge)
- CQR-5 (adherence)
- Satisfaction (M3)

Endpoints

- 1) Comparison of the **Biosecure score** to M0, M3 and M6
- 2) Comparison of the **rate of patients with high level of knowledge** and with **high adherence** to baseline, M3 and M6 and **patient satisfaction**

RESULTS

Demographic data

n = 79
Age = 50.4 ±14.7 years
Sex ratio (M/F) = 1.1

Adherence

Comparison of the rate of patients
with high adherence


	Baseline	M3	M6	p
% patients with high adherence	92.4	92.4	94.9	0.77

Satisfaction (/28)


24.9 ± 3.1

Knowledge

Comparison of the Biosecure score



Comparison of the rate of patients with high level (>84/100)



CONCLUSION AND RELEVANCE

Participation of the pharmacist in the MC allows for a **significant improvement of patients' knowledge** on their bDMARDs. Regarding adherence, no significant difference can be explained by an already high level. This study highlights the **positive impact of MC on patients' knowledge** of their SC bDMARD, as well as patient satisfaction.